刘俊良,秦 刚.PD-1/PD-L1抑制剂在骨肉瘤治疗中的研究进展[J].肿瘤学杂志,2022,28(11):922-926.
PD-1/PD-L1抑制剂在骨肉瘤治疗中的研究进展
Advances of PD-1/PD-L1 Inhibitors in Treatment of Osteosarcoma
投稿时间:2022-01-19  
DOI:10.11735/j.issn.1671-170X.2022.11.B006
中文关键词:  免疫治疗  骨肉瘤  PD-1/PD-L1  临床研究
英文关键词:immunotherapy  osteosarcoma  PD-1/PD-L1  clinical study
基金项目:国家自然科学基金项目(81860793);广西自然科学基金项目(2020JJA140375)
作者单位
刘俊良 广西中医药大学 
秦 刚 广西中医药大学第一附属医院 
摘要点击次数: 425
全文下载次数: 76
中文摘要:
      摘 要:骨肉瘤作为原发于骨细胞常见的恶性肿瘤,近几十年来疗效上没有本质上的提高。近年来PD-1/PD-L1抑制剂在多种恶性肿瘤中显现出了卓越的疗效,并在多个研究中显现出对骨肉瘤的抗肿瘤活性,有望进一步改善骨肉瘤,特别是转移及复发患者的治疗效果。全文综述总结近年PD-1/PD-L1抑制剂治疗骨肉瘤的主要进展。
英文摘要:
      Abstract: Osteosarcoma is the most common malignant tumor originating from bone cells, and its efficacy has not been substantially improved in recent decades. In recent years, PD-1/PD-L1 inhibitors have shown excellent efficacy in a variety of malignant tumors, including osteosarcoma. The efficacy of PD-1/PD-L1 inhibitors in treatment of osteosarcoma is expected to be further improved, especially in patients with metastasis and recurrence. This article reviews the main progress of PD-1/PD-L1 inhibitors in the treatment of osteosarcoma in recent years.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器